Skip to main content
S&P 5007,580.07-1.82%DOW51,770.31-1.09%NASDAQ25,437.00-2.86%BTC$77,415.00+0.36%ETH$2,246.32+1.22%GOLD$3,884.90-3.63%OIL$102.95+0.93%
Smart Investors Daily
SID Premium
PA

NASDAQ · PALI

Palisade Bio, Inc.

Healthcare · Biotechnology

$1.16

Down-$0.03 (-2.52%)

Updated Nov 2, 2026, 6:40 AM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
327.06M
P/E ratio
-1.46
Dividend yield
0.00%
52-week range
$1.10 – $2.86
Volume
3.09M
Avg. volume
8.34M

Price performance · PALI

PALI price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Oct 30, 2026

PALI closed at $1.16 after 20 trading sessions, down 20.55% for the selected period.

Last close
$1.16
Period change
-20.55%
Period low
$1.16
Period high
$1.59
Daily close
View OHLC price history
PALI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 30, 2026$1.18$1.20$1.115$1.163.09M
Oct 29, 2026$1.20$1.25$1.15$1.193.51M
Oct 28, 2026$1.22$1.22$1.10$1.1915.12M
Oct 27, 2026$1.22$1.255$1.17$1.206.01M
Oct 26, 2026$1.33$1.35$1.21$1.231.7M
Oct 23, 2026$1.35$1.37$1.28$1.331.33M
Oct 22, 2026$1.38$1.41$1.349$1.351.11M
Oct 21, 2026$1.44$1.46$1.39$1.401.43M
Oct 20, 2026$1.39$1.48$1.335$1.432.82M
Oct 19, 2026$1.41$1.46$1.32$1.341.84M
Oct 16, 2026$1.55$1.56$1.40$1.413.89M
Oct 15, 2026$1.50$1.56$1.48$1.541.82M
Oct 14, 2026$1.45$1.51$1.38$1.484.17M
Oct 13, 2026$1.56$1.5789$1.46$1.4651.59M
Oct 12, 2026$1.53$1.63$1.51$1.591.57M
Oct 9, 2026$1.49$1.57$1.47$1.541.84M
Oct 8, 2026$1.47$1.48$1.38$1.452.09M
Oct 7, 2026$1.46$1.48$1.44$1.48825.23K
Oct 6, 2026$1.51$1.55$1.47$1.491.97M
Oct 5, 2026$1.44$1.48$1.41$1.461.6M

Latest PALI news

The latest Smart Investors Daily articles mentioning PALI.

Stock researchCompany · Overview

PALI research

Overview

Company profile and research snapshot.

Company profile

Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$1.50
Implied upside
—
Analysts
—
PALI recent ratings
DateFirmRatingTarget
Oct 13, 2026HC Wainwright & Co.Buy—
Oct 9, 2026Raymond JamesOutperform—
Sep 23, 2026HC Wainwright & Co.Buy—
Jul 23, 2026OppenheimerOutperform—
Apr 9, 2026Wolfe ResearchOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 28, 2026

Palisade Bio Announces First Patient Dosed in Global Phase 2b ASCENTRA-UC Study Evaluating Once-Daily Oral PALI-2108 for the Treatment of Ulcerative Colitis

PALI-2108 is an investigational, gut-activated, once-daily oral PDE4 inhibitor prodrug designed for sustained exposure and anti-inflammatory activity with the potential to improve tolerability 29 of 30 planned U.S. sites already activated Global expansion progressing toward ~115 total sites, with CTA clearance in Canada and submissions under review in Europe and other international countries 12-week induction topline results expected Q4 2027 Denver, CO, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Palisade

Yahoo · Oct 20, 2026

Palisade Bio Presents Rapid Endoscopic Improvement and New Translational Evidence for PALI-2108 in Inflammatory Bowel Disease at UEG Week 2026

Five-patient Phase 1b Crohn’s disease cohort showed a 47.5% reduction in mean endoscopic disease activity and a 58.8% reduction in mean fecal calprotectin after 14 days Intestinal exposure and tissue analyses strengthen the rationale for an oral, once-daily therapy targeting the ileum and colon Phase 2b ASCENTRA-UC study enrolling; Phase 2a Crohn’s disease study being initiated Denver, CO, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a clinic

Benzinga · Oct 20, 2026

Palisade Bio Announces Findings Presented At United European Gastroenterology Week; Five-Patient Phase 1B Crohn’s Disease Cohort Showed 47.5% Reduction In Mean Endoscopic Disease Activity And 58.8% Reduction In Mean Fecal Calprotectin After 14 Days; Phase 2b ASCENTRA-UC Study Is Enrolling; Phase 2a Crohn’s Disease Study Being Initiated

linical and translational findings presented in one oral presentation and three moderated posters at United European Gastroenterology (UEG) Week 2026, held October 17–20 in Barcelona, Spain. The findings connect

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By